{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:50:47Z","timestamp":1787309447839,"version":"build-2736575974"},"reference-count":11,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,7,6]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>A 72-year-old woman with metastatic ER\/PR-positive breast cancer who had been on ribociclib and letrozole for 1\u2009year developed severe life-threatening colitis. She presented to emergency department with features of acute abdomen and diarrhoea. The diagnosis of colitis was confirmed radiologically as well as by histopathological examination of the biopsy specimen and the patient clinically improved after withholding ribociclib and receiving corticosteroids compatible with ribociclib-induced colitis. The mechanism of injury in CDK 4\/6 inhibitor-induced colitis is unknown but may be related to recruitment of inflammatory cells. Whether the development of colitis is associated with tumour response is an interesting and unanswered question.<\/jats:p>","DOI":"10.1136\/bcr-2021-242766","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T12:40:56Z","timestamp":1627303256000},"page":"e242766","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["CDK4\/6 inhibitor-induced colitis: a case report and review of the literature"],"prefix":"10.1136","volume":"14","author":[{"given":"Azhar Abbas","family":"Malik","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Abbas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin Mar","family":"Oo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-374X","authenticated-orcid":false,"given":"Zerlene","family":"Lim","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"2025082711515876000_14.7.e242766.1","doi-asserted-by":"publisher","DOI":"10.1159\/000339789"},{"key":"2025082711515876000_14.7.e242766.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.26"},{"key":"2025082711515876000_14.7.e242766.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155"},{"key":"2025082711515876000_14.7.e242766.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71159-3"},{"key":"2025082711515876000_14.7.e242766.5","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082711515876000_14.7.e242766.6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082711515876000_14.7.e242766.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0754"},{"key":"2025082711515876000_14.7.e242766.8","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"Monarch 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025082711515876000_14.7.e242766.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"2025082711515876000_14.7.e242766.10","unstructured":"Kurbacher CM , Schott A , Kurbacher AT . Qt-Interval prolongation during the treatment with ribociclib and endocrine agents in patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer: a real-world experience. Cancer Res 2020."},{"key":"2025082711515876000_14.7.e242766.11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0142"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-242766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:52:07Z","timestamp":1756320727000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-242766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":11,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,26]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bcr-2021-242766"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-242766","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}